LONDON—AstraZeneca PLC has agreed to buy the rights to a portfolio of inhaled drugs from Almirall SA in a deal worth up to $2.1 billion, a significant step toward expanding its respiratory business and the type of pipeline-boosting deal favored by Chief Executive Pascal Soriot.. The deal will give the U.K. drug maker a type of treatment for chronic obstructive pulmonary disease which it currently lacks, a new type of inhaler and a portfolio of pipeline drugs, potentially helping it compete better with rivals such as respiratory-market...
  